Treatment of prostatic carcinoma by pelvic lymphadenectomy, temporary Iridium-192 implant, and external irradiation.
Forty patients with clinically localized adenocarcinoma of the prostate have been treated by a combination of pelvic lymphadenectomy, temporary Iridium-192 implantation, and external irradiation with follow-up of one to five years. 192Ir implant delivers a minimum tumor dose of 3,000 rad to A2 and B1 lesions and 3,500 to B2 and C lesions. Two weeks later patients receive 4,000 rad of external irradiation to the prostate over four to five weeks. Patients with pelvic nodal metastases receive 5,000 rad to the pelvis with a midline block at 4,000 rad. All patients have had a complete local response as judged by clinical criteria. Prostate needle biopsies have been performed on 16 patients one year or less after treatment, with 15 biopsies benign. The technique appears to offer excellent local control of prostatic adenocarcinoma with acceptably low morbidity.
D000230:Adenocarcinoma / Q000628:therapy*; D001706:Biopsy; D001918:Brachytherapy; D005500:Follow-Up Studies; D006801:Humans; D007495:Iridium / Q000627:therapeutic use; D008197:Lymph Node Excision; D008297:Male; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011882:Radiotherapy, High-Energy
D011868:Radioisotopes; D007495:Iridium